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OBJECTIVES: As adjuvant endocrine therapy in women with early stage breast cancer 
prolongs disease free and overall survival, this study determined treatment continua- 
tion and ﬁrst treatment switch in breast cancer patients starting on tamoxifen and the         
determinants of discontinuation. METHODS: Patients with early stage breast cancer    
were selected from the Eindhoven Cancer Registry from 1998 to 2006 and linked to 
the PHARMO Network to select drug use during follow-up. Patients starting on       
tamoxifen were included in the study cohort. Continuous use of endocrine treatment 
was determined as the time between start and stop of therapy, allowing a 60 days gap 
between reﬁlls. The switch from tamoxifen to an aromatase inhibitor (anastrozole, 
exemestane or letrozole) was determined. Cox regression was used to identify inde-
pendent determinants of discontinuation of any endocrine treatment (tamoxifen and/
or aromatase inhibitor use) during ﬁve years of follow-up. RESULTS: A total of 1291 
new breast cancer patients started on tamoxifen. Of those, 29% had a treatment 
switch to: anastrozole (n  203), exemestane (n  113) or letrozole (N  64) with a 
mean duration until ﬁrst switch of 2.0 (SD  1.3) years. Of the patients followed for 
ﬁve years, 49% discontinued any endocrine treatment before the completion of ﬁve 
years. Multivariate analyses showed that discontinuers were less likely to be aged           
50–69 years (versus q 70 years; HR  0.74; 95%CI: 0.60–0.92). CONCLUSIONS: 
Only half of the breast cancer patients starting tamoxifen continued ﬁve years of 
endocrine treatment. Identiﬁcation of patients at risk of discontinuation will assist in          
the development of interventions to improve adherence.
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OBJECTIVES: Breast cancer (BC) incidence has steadily increased in France over the 
period 1980–2005 by a mean 2,4% yearly, whereas mortality decreased since the 
early 90’s by a mean 1.3% yearly. Two major factors may explain this apparent dis-
crepancy: on one hand, the extension of breast cancer screening coverage has permit-
ted an earlier diagnosis of cancer and, on the other hand, therapeutic progress has led 
to improved survival. Our objective was to quantify the relative role of these two 
factors in France over the period 1994–2005. METHODS: A simulation model 
was developed to extrapolate the evolution of the distribution of BC by stages at 
diagnosis as observed in the French registries in 1994 and 2006. The survival accord-
ing to the stage as observed in 1994 was then adjusted through an exponential model 
in order to ﬁt the observed breast cancer speciﬁc mortality rate as reported in the 
French vital statistics until the year 2005. RESULTS: In 2005, the absolute number    
of deaths for BC was 11,381 in France. Our model estimated the corresponding values 
that would be obtained respectively in absence of any modiﬁcation of the stage dis-
tribution between 1994 and 2006 (12,698 in 2005 i.e. 11% increase), or in absence 
of any modiﬁcation of survival by stage at diagnosis from 1994 onward (12,752 in 
2005, i.e. 11.5% increase). The contribution of therapeutic progress in the downward 
trend of BC speciﬁc mortality is in the same order of magnitude as the screening cover-
age extension. These two factors acted in an independent and additive manner on 
mortality reduction. CONCLUSIONS: The contrasted evolution of BC incidence and 
mortality cannot be explained solely by the extension of screening. Therapeutic inno-
vation played an important and equivalent role in the trends over the period 
1994–2005.
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OBJECTIVES: To describe trends and predictive factors in colorectal cancer (CRC) 
screening among Medicare beneﬁciaries METHODS: Cross-sectional analyses were 
conducted using data from the 2003 and 2005 Medicare Current Beneﬁciary Surveys 
(MCBS) when CRC speciﬁc questionnaire items were included. Bivariate and multi-
variate analyses between types of CRC screening tests and independent variables 
(i.e., socio-demographics, cancer history, and other cancer screening, were evaluated 
using chi square and logistic regression tests at an alpha of 0.05. All analyses were 
conducted using Stata 10.1 statistical software. RESULTS: A total of 31,772 Medicare 
beneﬁciaries participated in the MCBS in 2003 and 2005. Of this overall population, 
our study population included 26,561 (83.6%) community dwelling persons aged 50 
years and older. The majority of them were white and a slightly higher proportion 
were female (56.2%). The overall prevalence of self-reported life-time screening for 
CRC was 68.0% in 2003 and 70.8% in 2005. Bivariate analysis indicated a strong 
relationship between age, race, ethnicity and CRC screening. Multivariate logistic 
regression showed that being female (OR: 1.24; 95% CI 1.14–1.34), having previous 
history of cancer and participating in other cancer screening was associated with a 
higher likelihood of CRC screening. Beneﬁciaries of Other races excluding Blacks and 
those with additional Medicaid or no supplemental insurance were less likely to be 
associated with any CRC screening (p  0.05). CONCLUSIONS: In conclusion, 
slightly less than 7/10 Medicare beneﬁciaries in the community reported participating 
in CRC screening. These ﬁndings suggest that the current screening rate is still less 
than optimal. Gender and racial disparities observed indicate a need to increase aware-
ness of the importance of screening in this population.
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OBJECTIVES: There were 6701 new cases of cutaneous melanoma estimated in 2000 
and melanoma ranked as the ninth highest of all cancers in France. Prevalence data 
and stage distribution are not currently available. The objectives of this study were to 
determine the incidence by stage and 5-year survival rate in patients with melanoma 
occurring in 2000 and to estimate overall and metastatic cancer prevalence at the end 
of 2004. METHODS: This study was carried out by eight general cancer registries, 
members of the French cancer registry network FRANCIM. Data were collected 
through medical record and birth town hall database for vital status. The 5-year 
observed survival and its conﬁdence intervals were determined by the Kaplan-Meier 
method. The estimate of prevalence was performed according to the method proposed 
by Colonna et al. (Eur J Cancer 2001). RESULTS: 840 cases were analysed. The 
repartition of new melanoma cases in 2000 according to stage was: stage I (56.5%), 
stage II (21.1%), stage III (4.3%), stage IV (1.5%). For 16.6% of cases the stage was 
unknown. National estimation of melanoma diagnosed with initial metastasis was 102 
cases in 2000. The 5-year survival was 79.9% CI 95 [76.9%; 82.5%]. Survival was 
dependent on age (95.8% in patients less than 40 years and 38% in patients aged 80 
years) and stage of disease (91.9% stage I; 23.1% stage IV). The prevalence was esti-
mated to be 31,278 cases in France in 2004 with 2,310 involving metastasis (7.4%). 
CONCLUSIONS: This study brings important information on cutaneous melanoma 
epidemiology in France. These results are essential for the epidemiological surveillance 
of melanoma as well as for the evaluation of screening campaigns and needs in health 
care.
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OBJECTIVES: The main objective of this study was to describe the association 
between obesity and colorectal cancer (CRC) screening among Medicare beneﬁciaries 
in the United States. METHODS: Data from the 2005 Medicare Current Beneﬁciary 
Survey (MCBS) were used to identify CRC screening behavior identiﬁed by the positive 
history of screening for colorectal cancer and predictive factors for screening. To 
estimate the level of obesity, body mass index for each subject was calculated based 
on height and weight information available in the dataset. RESULTS: In the 2005 
MCBS, there were 15,769 beneﬁciaries (weighted estimates are 39,337,911 beneﬁcia-
ries) aged 50 years and older, i.e., eligible for colorectal cancer screening according 
to the clinical guidelines for screening. Over 60% of the beneﬁciaries were classiﬁed 
as obese, including 37% “obese” (30  BMI  35) and 25% “morbidly obese” (BMI 
 35) beneﬁciaries. Female beneﬁciaries were more likely to report receipt of CRC 
screening compared to men. Age was also a predictor for CRC screening, with older 
beneﬁciaries having higher odds of screening than those under 65 years old. It was 
also determined that Medicare beneﬁciaries from Black, Hispanic, and other racial 
groups were less likely to receive CRC screening than White beneﬁciaries. After con-
trolling for covariates, obese and morbidly obese beneﬁciaries had increased odds of 
screening for CRC compared to those classiﬁed as non-obese. (OR  1.15; 95% CI  
1.06–1.25; p  0.05). CONCLUSIONS: This study found that obesity is not a hinder-
ing factor for CRC screening. Further research is needed to gain better insight into 
adherence patterns of CRC screening to national guidelines, with particular focus on 
evaluating physicians’ ordering of screening tests.
